G-CSF
| G-CSF | |
|---|---|
| Term | G-CSF |
| Short definition | Fyarro (fy-AR-oh) A form of the drug sirolimus used to treat adults with malignant perivascular epitheloid cell tumor that has spread or cannot be surgically removed. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
G-CSF - A drug used under the brand names Neupogen, Zarxio, and Nivestym to treat neutropenia (a below-average white blood cell count), prevent infection, and prepare the blood for the collection of certain types of blood cells and under the brand name Granix for the treatment of neutropenia. G-CSF is used in patients with certain types of cancer and neutropenia caused by certain types of chemotherapy and in patients with severe chronic neutropenia not caused by cancer treatment. It is also used before an autologous stem cell transplant. G-CSF helps the bone marrow make more white blood cells. It's a kind of colony stimulating factor. Also called filgrastim and granulocyte colony stimulating factor
External links
- Medical encyclopedia article on G-CSF
- Wikipedia's article - G-CSF
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski